GSTM1 and chronic kidney disease: In order to assess the influence of inflammation on the effect of roxadustat, we extracted Hb changes in subjects with baseline CRP > ULN from six trials (Chen et al., 2019a; Akizawa et al., 2019c; NCT02174731, 2020; Coyne et al., 2021; Fishbane et al., 2021; Provenzano et al., 2021) (four trials for DD-CKD patients, two trials for NDD-CKD patients).